FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	OMB Number: 3235-0287							
Estimated average burden								
hours per response:	0.5							

Section obligat	this box if no lo n 16. Form 4 or ions may contir tion 1(b).		STAT		pursuan	t to Sectio	n 16(a	a) of the Se	curiti	es Exchan	ige Act of 1	VNERS 934	HIP	Estima	Numbe ated av per res	erage burden	0.5
1. Name and Address of Reporting Person* Esfandiari Javan (Last) (First) (Middle)					2. Issuer Name and Ticker or Trading Symbol <u>CHEMBIO DIAGNOSTICS, INC.</u> [CEMI] 3. Date of Earliest Transaction (Month/Day/Year) 03/16/2020					[] (Che	5. Relationship of Reporting Po (Check all applicable) Director X Officer (give title below) See Rem			10% Owner Other (specify below)			
555 WIR (Street) HAUPPA		OULEVARD	11788	Ļ			Date o	of Original I	-iled ((Month/Da	y/Year)	6. In Line)	oint/Group	Filing	(Check Appl	icable
(City)		tate)	(Zip)										-	ed by Mor		One Reporti	ing
		Та	ble I - Non	-Derivat	ive Se	ecuritie	s Ac	quired,	Disp	posed o	of, or Be	neficially	Owned		_		
Date				2. Transac Date (Month/Da	Execution Date		Code (Instr.					s Form Ily (D) or ollowing (I) (In		7. Nature of ndirect Beneficial Ownership Instr. 4)			
					Code V Amount (A) or (D)			r Price	Transaction(a)				ilisti. 4)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	rcise (Month/Day/Year) of tive	3A. Deemed Execution Date, if any (Month/Day/Yea	Code	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	e v	(A)	(D)	Date Exercisab		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	51(3)		
Option to purchase	\$2.36	03/16/2020		Α		188,064		(1)	0.	3/15/2027	Common Stock	188,064	\$0	188,00	64	D	

Explanation of Responses:

1. The option is scheduled to vest and become exercisable over three years, with one-third vesting as of March 16, 2021; one-third vesting as of March 16, 2023. Remarks:

Executive Vice President, Chief Science & Technology Officer

/s/ Mark L. Johnson, Attorney-03/18/2020 in-Fact for Javan Esfandiari

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.